No patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Patients must not have received systemic treatment with corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days prior to registration; inhaled or topical steroids, and adrenal replacement doses =<  mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
Known autoimmune disease requiring active treatment; subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of registration are excluded; inhaled or topical steroids, and adrenal replacement steroid doses =<  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first dose of study drug. Inhaled or topical steroids, and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease.
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization (unless used to treat investigational drug-related adverse events); inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other systemic immunosuppressive medications within  weeks
Known history or evidence of significant immunodeficiency due to underlying illness (e.g. human immunodeficiency virus [HIV]/acquired immunodeficiency syndrome [AIDS]) and/or medication (e.g. systemic corticosteroids or other immunosuppressive medications, including cyclosporine, azathioprine, interferons in the  weeks before the first dose of study treatment). Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisolone equivalent) or other immunosuppressive medications within  days of the first dose of study treatment. Inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of autoimmune disease
Participants with a condition requiring systemic treatment with corticosteroids of >  mg daily prednisone (or equivalent), or subjects requiring other immunosuppressive medications within  days of first treatment. Inhaled, topical, ophthalmologic, local steroid injections, and adrenal replacement steroid >  mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
Participants must not have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of start of study treatment; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Patient has a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first dose; inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization. Inhaled or topical steroids and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of uncontrolled autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of enrollment; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement steroid doses >  mg daily prednisone equivalent are permitted
Any condition requiring systemic treatment with either corticosteroids (>  mg/day prednisone or equivalent daily) or other immunosuppressive medications within  days prior to initiating protocol-indicated treatment.\r\n* In the absence of active autoimmune disease: Subjects are permitted the use of corticosteroids with minimal systemic absorption (e.g. topical, ocular, intra-articular, intranasal, and inhalational) =<  mg/day prednisone or equivalent daily; and physiologic replacement doses of systemic corticosteroids =<  mg/day prednisone or equivalent daily (e.g. hormone replacement therapy needed in patients with hypophysitis).
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids are permitted in the absence of active autoimmune disease
Any systemic steroid therapy or other form of immunosuppressive therapy within  days of the first dose of the vaccine; a physiologic dose of systemic corticosteroids may be approved; inhaled or topical steroids, and adrenal replacement steroid doses =<  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first treatment; inhaled or topical steroids, and adrenal replacement steroid  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Current immunosuppressive therapy including >  mg/day of prednisone within  days of enrollment is not permitted; inhaled or topical steroids, and adrenal replacement steroid doses =<  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of enrollment; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to  mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune disease
Any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days prior to first dose of study drug; inhaled or topical steroids and adrenal replacement steroid doses >  mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalent) or other immunosuppressive medications within  days of start. Inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
Condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to study treatment (Note: Inhaled and topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.)
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization; inhaled or topical steroids and adrenal replacement steroid doses > mg daily prednisone equivalent, are permitted in the absence of uncontrolled autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses >  mg daily prednisone equivalent are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of registration; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses >  mg daily prednisone equivalent are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization; inhaled or topical steroids are permitted in the absence of active autoimmune disease
Any condition requiring treatment with corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medication within  days of the first dose of study drug; inhaled, topical, ocular or intra-articular steroids and adrenal replacement steroid doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of study drug administration are excluded
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to  mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune disease
Patients with a condition requiring chronic systemic treatment with either corticosteroids(>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of treatment start. Inhaled or topical steroids, and adrenal replacement steroid doses>  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects are excluded if they have a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of study drug administration; inhaled or topical steroids and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease; drugs with a predisposition to hepatoxicity should be used with caution in patients treated with nivolumab?containing regimen
Condition requiring active systemic treatment with either corticosteroids (> mg daily prednisone equivalent) or other immunosuppressive medications
Patient with any condition requiring systemic treatment with either corticosteroids (>  mg daily of prednisone or equivalent) or other immunosuppressive medication within  days before randomization
Participants with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days of study treatment except for adrenal replacement steroid doses >  mg daily prednisone equivalent in the absence of active autoimmune disease. Note: treatment with a short course of steroids (<  days) up to  days prior to initiating study treatment is permitted
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days prior to the first dose of study drug; inhaled steroids and adrenal replacement steroid doses up to  mg daily prednisone equivalent are permitted (although not encouraged) in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization
Use of systemic corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days of study drug administration, with exception of inhaled or topical steroids.
A condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization; corticosteroids with minimal systemic absorption (inhaled or topical steroids) and adrenal replacement steroid doses >  mg daily prednisone equivalent are permitted in the absence of active autoimmune disease
Patients must not have received systemic treatment with corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days prior to sub-study registration; inhaled or topical steroids, and adrenal replacement doses =<  mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids ( >  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first treatment.
No known autoimmune disease requiring active treatment. Subjects with a condition requiring systemic treatment with either corticosteroids (> mg daily prednisone equivalent) or other immunosuppressive medications within  days of enrollment. Inhaled or topical steroids, and adrenal replacement steroid doses ?  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Any condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other systemic immunosuppressive medications within  weeks
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of start; inhaled or topical steroids, and adrenal replacement steroid doses >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Patients with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of randomization; inhaled or topical steroids and adrenal replacement steroid doses =<  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Subjects with condition requiring systemic treatment with either corticosteroids (> mg daily prednisone/equivalent) or other immunosuppressive medications within  days of study drug administration
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first study treatment with nivolumab; inhaled or topical steroids, and adrenal replacement steroid >  mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease
Patients with a condition requiring systemic treatment with either corticosteroids (?  mg daily prednisone or equivalent) or other immunosuppressive medications within  days of study drug administration. Inhaled or topical steroids are permitted in the absence of active autoimmune disease.
Any condition requiring systemic treatment with corticosteroids (>  mg daily prednisone or equivalent) or other immunosuppressive medications within  days prior to first dose of study drug; inhaled or topical steroids and adrenal replacement steroid doses >  mg daily prednisone or equivalent are permitted in the absence of active autoimmune disease
Subjects with a condition requiring systemic treatment with either corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medications within  days of first dose of study drug; inhaled or topical steroids, and adrenal replacement steroid doses are permitted in the absence of active autoimmune disease
Any condition requiring treatment with corticosteroids (>  mg daily prednisone equivalent) or other immunosuppressive medication within  days of the first dose of study drug; inhaled, topical, ocular or intra-articular corticosteroids and adrenal replacement steroid doses =<  mg daily prednisone equivalents are permitted in the absence of active autoimmune disease